Piper Jaffray Cos. Analysts Give Reata Pharmaceuticals Inc. (RETA) a $33.00 Price Target
Reata Pharmaceuticals Inc. (NASDAQ:RETA) has been given a $33.00 price objective by research analysts at Piper Jaffray Cos. in a research note issued to investors on Friday. The firm presently has a a “buy” rating on the stock. Piper Jaffray Cos.’s price target indicates a potential upside of 17.82% from the stock’s previous close.
A number of other analysts have also recently commented on RETA. Zacks Investment Research cut shares of Reata Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, September 20th. Cowen and Company started coverage on shares of Reata Pharmaceuticals in a research note on Monday, June 20th. They issued an “outperform” rating and a $22.00 target price for the company. Finally, Citigroup Inc. started coverage on shares of Reata Pharmaceuticals in a research note on Monday, June 20th. They issued a “buy” rating and a $32.00 target price for the company.
Shares of Reata Pharmaceuticals (NASDAQ:RETA) traded up 4.32% during mid-day trading on Friday, hitting $29.22. 160,603 shares of the stock were exchanged. The stock’s 50-day moving average price is $23.49 and its 200-day moving average price is $20.03. The company’s market cap is $652.34 million. Reata Pharmaceuticals has a 52-week low of $11.03 and a 52-week high of $32.22.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/07/piper-jaffray-cos-analysts-give-reata-pharmaceuticals-inc-reta-a-33-00-price-target.html
Reata Pharmaceuticals (NASDAQ:RETA) last released its quarterly earnings results on Thursday, August 11th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.03. The firm earned $12.40 million during the quarter. Equities research analysts anticipate that Reata Pharmaceuticals will post ($0.54) earnings per share for the current fiscal year.
In other Reata Pharmaceuticals news, Director Jack Nielsen acquired 1,780 shares of the firm’s stock in a transaction on Monday, August 22nd. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $30,260.00. Following the purchase, the director now owns 1,780 shares in the company, valued at approximately $30,260. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Colin John Meyer acquired 7,000 shares of the firm’s stock in a transaction on Tuesday, August 16th. The shares were acquired at an average price of $16.26 per share, with a total value of $113,820.00. Following the completion of the purchase, the insider now owns 27,172 shares in the company, valued at approximately $441,816.72. The disclosure for this purchase can be found here. Company insiders own 62.40% of the company’s stock.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.